Want to see QURE full AI Analyst Report?
QURE Stock Chart & Stats
$17.58
-$1.39(-7.88%)
At close: 4:00 PM EST
$17.58
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$8.73 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)2.37M
Market Cap
$2.73B
Enterprise Value$984.95
Total Cash (Recent Filing)$586.55M
Total Debt (Recent Filing)$63.32M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Jul 29, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.51
Shares Outstanding68,012,540
10 Day Avg. Volume1,307,254
30 Day Avg. Volume2,365,761
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$66.33Price Target Upside277.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.66
Revenue Forecast (FY)$20.99M
Bulls Say, Bears Say
Bulls Say
Regulatory Path For AMT-130FDA alignment to accept three-year Phase I/II AMT-130 data as the primary basis for an accelerated BLA materially reduces regulatory uncertainty and shortens the timeline to potential approval. This durable regulatory clarity strengthens uniQure's path to commercialization and future revenue/royalty streams if confirmatory studies proceed as planned.
Positive Early Clinical Signal (AMT-260)Early AMT-260 clinical activity and favorable short-term safety support the platform's ability to generate meaningful efficacy signals in neurology. If higher-dose cohorts sustain consistent responses, this diversifies uniQure's pipeline into epilepsy, expands addressable markets, and strengthens long-term commercial potential beyond single-asset dependency.
Strengthened Funding From Equity RaiseA sizeable, completed equity raise meaningfully bolsters liquidity and extends the cash runway, reducing near-term refinancing risk. This funding supports late-stage regulatory submissions, initiation of confirmatory trials, and commercialization activities, enabling sustained R&D investment and execution on durable strategic objectives over the coming months.
Bears Say
High Cash BurnPersistent, large negative operating cash flow indicates the company is not self-funding operations and must rely on external financing or partner payments. Over a multi-month horizon this elevates execution risk if capital markets tighten or milestone timing shifts, and it can force dilution or cuts to programs if funding falls short.
Low Recurring Revenue BaseA small revenue base relative to high R&D and operating costs means margins are structurally unsustainable absent new product launches or reliably recurring partner income. This makes profitability and cash generation contingent on successful approvals, commercialization, or continued partnership deals—outcomes that are uncertain and multi-period in realization.
Balance-sheet Volatility And Prior Negative EquityHistorical swings including a period of negative equity and inconsistent capital structure raise concerns about financial resilience. Such volatility can limit strategic flexibility, increase perceived financing risk, and lead to future dilution or restrictive covenant exposure, all of which can undermine long-term investment in R&D and commercialization.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $8.73 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $2.73B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 6 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.865 by $0.015.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.82.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 68,012,540 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.865. Following the earnings report the stock price went up 2.321%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.33 (277.32% Upside)
$66.33 (277.32% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 89.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $966.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.63%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Stock 12 Month Forecast
Average Price Target
$66.33
▲(277.32% Upside)
Technical Analysis
Ownership Overview
2.04% Insiders
12.35% Mutual Funds
1.07% Other Institutional Investors
76.54% Public Companies and
Individual Investors